Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
86 participants
OBSERVATIONAL
2018-10-17
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Lipoprotein Composition and Function in Pediatric Psoriasis Before and After Treatment
NCT03791216
Impact of the Severity of Pediatric Psoriasis on Childhood Body Mass Index
NCT00879944
Etanercept (Enbrel®) in Psoriasis - Pediatrics
NCT00078819
To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
NCT00050648
Study to Help Understand the Action of the Drug Etanercept for the Adult Patient With Psoriasis
NCT00116181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Psoriasis patients
Patients (of any age) who developed psoriasis before 12 years of age and who have no family history of psoriasis in either parent.
Saliva or buccal sample
Saliva or buccal sample
Parents of psoriasis patients
Parents of patients who developed psoriasis before 12 years of age
Saliva or buccal sample
Saliva or buccal sample
Up to third-degree family members with or without psoriasis
Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
Saliva or buccal sample
Saliva or buccal sample
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Saliva or buccal sample
Saliva or buccal sample
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parents of patients who developed psoriasis before 12 years of age
* Up to third-degree family members (first cousin, grandparent, great-grandparent) with or without psoriasis, if family history is indicated.
Exclusion Criteria
* Patients, parents, and other family member unable to give written informed consent.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Psoriasis Foundation
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Northwestern University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amy Paller
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amy Paller, MD
Role: PRINCIPAL_INVESTIGATOR
Northwestern University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-2259
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.